Abstract 1708P
Background
Since China implemented the regulations on adjusting the approval process of imported drugs in 2017, the integration of China into the global development of novel anticancer drugs has accelerated. The changing registration pathways for these products inspire us to present this data analysis.
Methods
Based on the review reports of approved global anticancer drugs from the database of the Center of Drug Evaluation of China, the cancer type, scope and timeline of pivotal supporting trials for each indication were extracted by the end of 2022. The distribution of registration pathways was explored using the number of indications as the key indicator.
Results
A total of 83 approved indications were retrieved. Participating in synchronous global studies (39, 47.0%) was the most common registration pathway, which was divided into dose expansion/phase II (4, 4.8%) and confirmatory studies (35, 42.2%). Launching China-dominant studies was another main pathway (35, 42.2%), including bridging (26, 31.3%) and confirmatory studies (10, 12.0%). Clinical studies in China were exempted in 15 (18.1%) indications. Multiple pathways were used to support 7 (8.4%) indications. The number of indications supported by China-dominant studies decreased from 19 (2017-2019) to 15 (2020-2022), while that of synchronous global studies increased from 15 (2017-2019) to 23 (2020-2022). Among the 9 indications for esophageal, gastric and hepatocellular cancer, eight (88.9%) were approved by global studies. The median days between China and the first global approval was 371 in indications supported by global studies, compared with 1326 in that supported by China-dominant studies.
Table: 1708P
No. of indications | ||||||||
Year | Dose-expansion/phase II | Global confirmatory studies | Synchronous global studies | Bridging studies | China-dominant confirmatory studies | China-dominant studies | Exemption of clinical studies in China | Total |
2015 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 |
2017 | 1 | 2 | 3 | 3 | 2 | 5 | 1 | 7 |
2018 | 0 | 5 | 5 | 5 | 2 | 6 | 0 | 10 |
2019 | 2 | 5 | 7 | 5 | 3 | 8 | 4 | 18 |
2020 | 0 | 9 | 9 | 4 | 1 | 5 | 5 | 19 |
2021 | 0 | 8 | 8 | 4 | 2 | 6 | 4 | 17 |
2022 | 1 | 5 | 6 | 4 | 0 | 4 | 1 | 11 |
Total (%) | 4(4.8%) | 35(42.2%) | 39(47.0%) | 26(31.3%) | 10(12.0%) | 35(42.2%) | 15(18.1%) | 83(100.0%) |
Median days between China and global approval | 1399 | 365 | 371 | 1230 | 2082 | 1326 | 2064 | 1045 |
Conclusions
Participating in synchronous global studies is the most common and time-saving registration pathway in China for globally developed novel anticancer drugs in recent years, especially for Chinese high-prevalent cancers. Efforts should be made to help China join more global early-phase studies in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1717P - Management of patients during a digital healthcare record system transition: A phase I unit experience
Presenter: Lyra Del Rosario
Session: Poster session 23
1718P - Impact of the economic status of the patient's country of residence on the outcome of oncology clinical trials
Presenter: Saki Nishiyama
Session: Poster session 23
1719P - Decentralized clinical trials: Is there a space in Italy?
Presenter: Celeste Cagnazzo
Session: Poster session 23
1720P - Experience in the provision of oncology services immediately after a major disaster
Presenter: Burak Aktas
Session: Poster session 23
1721P - Self-assessment tool and best-practice sharing to support hospitals in improving the quality of multi-disciplinary teams in lung cancer care
Presenter: Ernest Nadal
Session: Poster session 23
1722P - Factors contributing to differences in evidence compliance rate in cancer treatment among second opinion cases
Presenter: Tomomi Sanomachi
Session: Poster session 23
1723P - Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 23
1724P - Improving access to breast cancer diagnosis and treatment through navigation: Evaluation of a one-year pilot project in Botswana
Presenter: Ariane Migeotte
Session: Poster session 23
1725P - Genetic counselling for cancer in EU member states: Review and foundation for consensus recommendations
Presenter: J. Matt McCrary
Session: Poster session 23
1726P - Optimizing oncology drug spending in a cancer centre in Ireland
Presenter: Ruth Kieran
Session: Poster session 23